Literature DB >> 8214185

Plasma and platelet excitatory amino acids in psychiatric disorders.

C A Altamura1, M C Mauri, A Ferrara, A R Moro, G D'Andrea, F Zamberlan.   

Abstract

Plasma and platelet levels of excitatory amino acids were measured in 38 psychiatric out-patients and in 19 comparison subjects; the patients had DSM-III-R diagnoses of organic mental disorders (N = 3), mood disorders (N = 15), schizophrenia (N = 13), and anxiety disorders (N = 7). The glutamate plasma levels were significantly higher in the patients with mood disorders than in the comparison group.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8214185     DOI： 10.1176/ajp.150.11.1731

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  66 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

3.  Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.

Authors:  Tomislav Kovačević; Ivan Skelin; Luciano Minuzzi; Pedro Rosa-Neto; Mirko Diksic
Journal:  Brain Res Bull       Date:  2012-01-31       Impact factor: 4.077

4.  Activation of the mGlu7 receptor elicits antidepressant-like effects in mice.

Authors:  Agnieszka Palucha; Kinga Klak; Piotr Branski; Herman van der Putten; Peter J Flor; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2007-07-12       Impact factor: 4.530

Review 5.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

6.  White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress.

Authors:  Sara Poletti; Irene Bollettini; Cristina Lorenzi; Alice Vitali; Silvia Brioschi; Alessandro Serretti; Cristina Colombo; Francesco Benedetti
Journal:  Mol Neurobiol       Date:  2018-05-22       Impact factor: 5.590

Review 7.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 8.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 9.  The As and Ds of stress: metabolic, morphological and behavioral consequences.

Authors:  Lawrence P Reagan; Claudia A Grillo; Gerado G Piroli
Journal:  Eur J Pharmacol       Date:  2008-02-26       Impact factor: 4.432

10.  Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Giacomo Salvadore; Ricardo Alberto Moreno; Maria Concepción Garcia Otaduy; Kalil T Chaim; Wagner F Gattaz; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.